Crossmark

Type 2 myocardial infarction and myocardial injury: eligibility for novel medical therapy to derisk clinical trials

Crossref DOI link: https://doi.org/10.1136/openhrt-2021-001633

Published Online: 2021-06-02

Published Print: 2021-06

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Sykes, Robert https://orcid.org/0000-0003-1010-5474
Briscoe, Michael

Krysztofiak, Thomas

Peck, Oliver

Mangion, Kenneth

Berry, Colin
Funding

Funding for this research was provided by:

UK Research and Innovation (MR/S018905/1)

British Heart Foundation (PG/17/2532884, RE/13/5/30177, RE/18/6/34217)
License Information

License valid from 2021-06-02